STOCK TITAN

[Form 4/A] Iridex Corp Amended Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4/A
Rhea-AI Filing Summary

This Form 4/A is an amendment to a previously filed Form 4 for Scott Shuda, a Director of Iridex Corp (IRIX), reporting a stock option grant on June 13, 2025. The original filing was made on June 17, 2025.

Key details of the transaction:

  • Granted 53,000 stock options to purchase common stock
  • Exercise price set at $0.94 per share
  • Options expire on June 13, 2032
  • Vesting occurs at earlier of: one-year anniversary of grant date or 2026 annual stockholder meeting

The options were granted under the company's 2008 Equity Incentive Plan and are exempt under Rule 16b-3. The filing was signed by Nilo De Castro as attorney-in-fact for Scott Shuda on June 24, 2025.

Questo Modulo 4/A è una modifica a un Modulo 4 precedentemente presentato per Scott Shuda, Direttore di Iridex Corp (IRIX), che segnala una concessione di opzioni su azioni avvenuta il 13 giugno 2025. La presentazione originale è stata effettuata il 17 giugno 2025.

Dettagli principali della transazione:

  • Concesse 53.000 opzioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a $0,94 per azione
  • Le opzioni scadono il 13 giugno 2032
  • Il vesting avviene al primo tra: anniversario di un anno dalla data di concessione o assemblea annuale degli azionisti del 2026

Le opzioni sono state concesse nell'ambito del Piano di Incentivazione Azionaria 2008 della società e sono esenti ai sensi della Regola 16b-3. Il documento è stato firmato da Nilo De Castro in qualità di procuratore per Scott Shuda il 24 giugno 2025.

Este Formulario 4/A es una enmienda a un Formulario 4 previamente presentado para Scott Shuda, Director de Iridex Corp (IRIX), que reporta una concesión de opciones sobre acciones el 13 de junio de 2025. La presentación original se realizó el 17 de junio de 2025.

Detalles clave de la transacción:

  • Se otorgaron 53,000 opciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $0.94 por acción
  • Las opciones expiran el 13 de junio de 2032
  • La adquisición se produce lo antes posible entre: el primer aniversario de la fecha de concesión o la reunión anual de accionistas de 2026

Las opciones fueron otorgadas bajo el Plan de Incentivos de Capital de 2008 de la empresa y están exentas bajo la Regla 16b-3. La presentación fue firmada por Nilo De Castro como apoderado de Scott Shuda el 24 de junio de 2025.

이 Form 4/A는 Iridex Corp (IRIX)의 이사인 Scott Shuda에 대해 이전에 제출된 Form 4의 수정본으로, 2025년 6월 13일에 주식 옵션 부여를 보고합니다. 원래 제출은 2025년 6월 17일에 이루어졌습니다.

거래 주요 내용:

  • 보통주를 구매할 수 있는 53,000 주식 옵션 부여
  • 행사가격은 주당 $0.94
  • 옵션 만료일은 2032년 6월 13일
  • 베스팅은 부여일 1주년 또는 2026년 연례 주주총회 중 빠른 시점에 발생

이 옵션은 회사의 2008년 주식 인센티브 계획에 따라 부여되었으며, Rule 16b-3에 따라 면제됩니다. 제출 서류는 2025년 6월 24일 Scott Shuda의 대리인인 Nilo De Castro가 서명했습니다.

Ce formulaire 4/A est un amendement à un formulaire 4 précédemment déposé pour Scott Shuda, administrateur d'Iridex Corp (IRIX), signalant une attribution d'options d'achat d'actions le 13 juin 2025. Le dépôt initial a été effectué le 17 juin 2025.

Détails clés de la transaction :

  • Attribution de 53 000 options d'achat d'actions ordinaires
  • Prix d'exercice fixé à 0,94 $ par action
  • Expiration des options le 13 juin 2032
  • L'acquisition des droits intervient au premier des deux événements suivants : un an après la date d'attribution ou l'assemblée annuelle des actionnaires de 2026

Les options ont été attribuées dans le cadre du Plan d'Incitation au Capital de 2008 de la société et sont exemptées selon la Règle 16b-3. Le dépôt a été signé par Nilo De Castro en tant que mandataire de Scott Shuda le 24 juin 2025.

Dieses Formular 4/A ist eine Änderung zu einem zuvor eingereichten Formular 4 für Scott Shuda, einen Direktor von Iridex Corp (IRIX), und berichtet über eine Gewährung von Aktienoptionen am 13. Juni 2025. Die ursprüngliche Einreichung erfolgte am 17. Juni 2025.

Wesentliche Details der Transaktion:

  • Gewährung von 53.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf $0,94 pro Aktie
  • Optionen laufen am 13. Juni 2032 ab
  • Vesting erfolgt zum früheren Zeitpunkt von: einjährigem Jubiläum des Gewährungsdatums oder der jährlichen Hauptversammlung 2026

Die Optionen wurden im Rahmen des Aktienanreizplans 2008 des Unternehmens gewährt und sind gemäß Regel 16b-3 ausgenommen. Die Einreichung wurde am 24. Juni 2025 von Nilo De Castro als Bevollmächtigter für Scott Shuda unterzeichnet.

Positive
  • Director Scott Shuda received a significant stock option grant of 53,000 shares at $0.94 per share, demonstrating board alignment with shareholder interests through equity-based compensation
Negative
  • None.

Questo Modulo 4/A è una modifica a un Modulo 4 precedentemente presentato per Scott Shuda, Direttore di Iridex Corp (IRIX), che segnala una concessione di opzioni su azioni avvenuta il 13 giugno 2025. La presentazione originale è stata effettuata il 17 giugno 2025.

Dettagli principali della transazione:

  • Concesse 53.000 opzioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a $0,94 per azione
  • Le opzioni scadono il 13 giugno 2032
  • Il vesting avviene al primo tra: anniversario di un anno dalla data di concessione o assemblea annuale degli azionisti del 2026

Le opzioni sono state concesse nell'ambito del Piano di Incentivazione Azionaria 2008 della società e sono esenti ai sensi della Regola 16b-3. Il documento è stato firmato da Nilo De Castro in qualità di procuratore per Scott Shuda il 24 giugno 2025.

Este Formulario 4/A es una enmienda a un Formulario 4 previamente presentado para Scott Shuda, Director de Iridex Corp (IRIX), que reporta una concesión de opciones sobre acciones el 13 de junio de 2025. La presentación original se realizó el 17 de junio de 2025.

Detalles clave de la transacción:

  • Se otorgaron 53,000 opciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $0.94 por acción
  • Las opciones expiran el 13 de junio de 2032
  • La adquisición se produce lo antes posible entre: el primer aniversario de la fecha de concesión o la reunión anual de accionistas de 2026

Las opciones fueron otorgadas bajo el Plan de Incentivos de Capital de 2008 de la empresa y están exentas bajo la Regla 16b-3. La presentación fue firmada por Nilo De Castro como apoderado de Scott Shuda el 24 de junio de 2025.

이 Form 4/A는 Iridex Corp (IRIX)의 이사인 Scott Shuda에 대해 이전에 제출된 Form 4의 수정본으로, 2025년 6월 13일에 주식 옵션 부여를 보고합니다. 원래 제출은 2025년 6월 17일에 이루어졌습니다.

거래 주요 내용:

  • 보통주를 구매할 수 있는 53,000 주식 옵션 부여
  • 행사가격은 주당 $0.94
  • 옵션 만료일은 2032년 6월 13일
  • 베스팅은 부여일 1주년 또는 2026년 연례 주주총회 중 빠른 시점에 발생

이 옵션은 회사의 2008년 주식 인센티브 계획에 따라 부여되었으며, Rule 16b-3에 따라 면제됩니다. 제출 서류는 2025년 6월 24일 Scott Shuda의 대리인인 Nilo De Castro가 서명했습니다.

Ce formulaire 4/A est un amendement à un formulaire 4 précédemment déposé pour Scott Shuda, administrateur d'Iridex Corp (IRIX), signalant une attribution d'options d'achat d'actions le 13 juin 2025. Le dépôt initial a été effectué le 17 juin 2025.

Détails clés de la transaction :

  • Attribution de 53 000 options d'achat d'actions ordinaires
  • Prix d'exercice fixé à 0,94 $ par action
  • Expiration des options le 13 juin 2032
  • L'acquisition des droits intervient au premier des deux événements suivants : un an après la date d'attribution ou l'assemblée annuelle des actionnaires de 2026

Les options ont été attribuées dans le cadre du Plan d'Incitation au Capital de 2008 de la société et sont exemptées selon la Règle 16b-3. Le dépôt a été signé par Nilo De Castro en tant que mandataire de Scott Shuda le 24 juin 2025.

Dieses Formular 4/A ist eine Änderung zu einem zuvor eingereichten Formular 4 für Scott Shuda, einen Direktor von Iridex Corp (IRIX), und berichtet über eine Gewährung von Aktienoptionen am 13. Juni 2025. Die ursprüngliche Einreichung erfolgte am 17. Juni 2025.

Wesentliche Details der Transaktion:

  • Gewährung von 53.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf $0,94 pro Aktie
  • Optionen laufen am 13. Juni 2032 ab
  • Vesting erfolgt zum früheren Zeitpunkt von: einjährigem Jubiläum des Gewährungsdatums oder der jährlichen Hauptversammlung 2026

Die Optionen wurden im Rahmen des Aktienanreizplans 2008 des Unternehmens gewährt und sind gemäß Regel 16b-3 ausgenommen. Die Einreichung wurde am 24. Juni 2025 von Nilo De Castro als Bevollmächtigter für Scott Shuda unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shuda Scott

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/17/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock (right to buy)(1) $0.94 06/13/2025 A 53,000 (2) 06/13/2032 Common Stock 53,000 $0 53,000 D
Explanation of Responses:
1. This option was granted pursuant to the Company's 2008 Equity Incentive Plan, as amended, and is exempt pursuant to Rule16b-3.
2. All shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the Company's 2026 annual meeting of stockholders.
/s/ Nilo De Castro, Attorney-in-fact for Scott Shuda 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did IRIX director Scott Shuda receive on June 13, 2025?

Scott Shuda received 53,000 stock options to buy IRIX common stock at an exercise price of $0.94 per share. These options were granted under the Company's 2008 Equity Incentive Plan and will expire on June 13, 2032.

When do Scott Shuda's IRIX stock options vest?

The stock options will vest and become exercisable upon the earlier of: (1) the one-year anniversary of the grant date (June 13, 2026) or (2) IRIX's 2026 annual meeting of stockholders.

Why did IRIX file a Form 4/A amendment for Scott Shuda?

The Form 4/A was filed as an amendment to the original Form 4 filed on June 17, 2025. This amended filing reports Scott Shuda's acquisition of 53,000 stock options as a director of IRIX.

What is Scott Shuda's role at IRIX?

According to the filing, Scott Shuda serves as a Director of IRIDEX Corporation (IRIX). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What was the total value of IRIX stock options granted to Scott Shuda in June 2025?

The filing shows that Scott Shuda received 53,000 stock options with an exercise price of $0.94 per share. The options were reported with a price of $0 as they were granted as equity compensation, not purchased.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

21.83M
12.06M
27.9%
18.63%
1.8%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW